Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Gillick

Neurological Surgery Newark, NJ Medical Doctor

NPI 1821499344 CMS profile 2788675

90 Bergen St Ste 8100, Ste 8100, Newark, NJ 07103

Open in the dashboard

General payments

$89,856

251 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Gillick of Newark, NJ is reported in the CMS Open Payments database as having received $89,856 across 251 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $30,146 45
2024 General $20,756 57
2023 General $14,427 46
2022 General $16,086 46
2021 General $929 11
2020 General $793 6
2019 General $6,719 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Gillick
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to John Gillick were reported at $30,146. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year John Gillick Neurological Surgery median Middle half National median
2019 $6,719 $582 $138–$3,006 $163
2020 $793 $294 $76–$2,174 $114
2021 $929 $387 $105–$2,432 $132
2022 $16,086 $542 $139–$2,989 $149
2023 $14,427 $534 $145–$2,697 $160
2024 $20,756 $574 $155–$3,046 $164
2025 $30,146 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $37,620 66 payments
  2. Baxter Healthcare $22,503 59 payments
  3. Stryker Corporation $8,173 55 payments
  4. Globus Medical, Inc. $6,106 16 payments
  5. Bioventus LLC $4,783 9 payments
  6. 4WEB, Inc. $3,077 10 payments
  7. NuVasive, Inc. $2,157 20 payments
  8. Mitsubishi Tanabe Pharma America, Inc. $1,800 1 payment
  9. Alphatec Spine, Inc $1,741 5 payments
  10. Mitsubishi Tanabe Pharma Development America, Inc. $1,200 1 payment
  11. Other $697 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $31,975 9 payments
  2. Consulting Fee $19,160 10 payments
  3. Travel and Lodging $18,983 55 payments
  4. Food and Beverage $17,098 176 payments
  5. Education $2,640 1 payment
Products named General payments · program years 2019–2025
  1. CD HORIZON SPINAL SYSTEM $33,016 29 payments
  2. FLOSEAL Surgical Care $11,978 8 payments
  3. ACTIFUSE $4,872 43 payments
  4. SPINE TRUSS SYSTEM $3,077 10 payments
  5. FLOSEAL Surgical Care $2,902 3 payments
  6. TRITANIUM $2,873 21 payments
  7. O-ARM $2,570 18 payments
  8. BONESCALPEL & SONICONE (O.R.) $2,259 2 payments
  9. EVEREST SPINAL SYSTEM $1,921 6 payments
  10. SABLE $1,588 2 payments
  11. Other $15,506 108 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

195

Median for Neurosurgery: 83

Drug cost

$2,220

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 78 $824
Cyclobenzaprine Hcl Generic 33 $600
Pregabalin Generic 32 $453
Baclofen Generic 23 $218
Tizanidine Hcl Generic 29 $124

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$30,302

Medicare's payments for the services billed

Medicare patients

62

Average age 69

Services billed

149

33 women, 29 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 50%
Ischemic heart disease 34%
Depression 34%
COPD 23%
Chronic kidney disease 19%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

251 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record